Concord Wealth Partners Fate Therapeutics Inc Transaction History

Concord Wealth Partners

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 27, 2023	BUY	$9.86 - $23.83 $69 - $166	7 New	7 $0
Q2 2022 Aug 04, 2022	SELL	$17.78 - $42.39 $6,418 - $15,302	-361 Reduced 95.0%	19 $0
Q1 2022 Apr 20, 2022	SELL	$29.67 - $60.28 $15,873 - $32,249	-535 Reduced 58.47%	380 $15,000
Q4 2021 Jan 21, 2022	BUY	$47.84 - $64.34 $39,563 - $53,209	827 Added 939.77%	915 $54,000
Q3 2021 Nov 09, 2021	BUY	$59.27 - $95.73 $4,504 - $7,275	76 Added 633.33%	88 $5,000
Q2 2021 Jul 29, 2021	BUY	$67.25 - $92.52 $807 - $1,110	12 New	12 $1,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.